A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is
In order to define the effects and safety of cyclosporin A (CsA) in systemic lupus erythematosus (SLE), we conducted an open clinical trial with 16 SLE patients. During an observation period of up to 64 months and an average treatment period of 30.3 months, 16 SLE patients, who did not have adequate disease control or experienced side-effects with their previous immunosuppressive therapy, were treated with CsA (3-5 mg/kg). In 3/16 patients, CsA treatment was discontinued because ofdoi:10.1093/rheumatology/35.7.669 pmid:8670602 fatcat:ivkmgmirl5dajdbhpio4d2be4i